• OPEN AN ACCOUNT
Indian Indices
Sensex
76,059.77 -331.62
( -0.43%)
Global Indices
Nasdaq
51,969.87 237.22
(0.46%)
Dow Jones
7,434.30 5.00
(0.07%)
Hang Seng
64,397.99 -2,024.61
(-3.05%)
Nikkei 225
10,738.51 99.34
(0.93%)
Forex
USD-INR
96.67 0.19
(0.20%)
EUR-INR
110.18 0.12
(0.10%)
GBP-INR
129.04 -0.01
(0.00%)
JPY-INR
0.59 0.00
(-0.04%)

EQUITY - MARKET SCREENER

Cipla Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500087
INE059A01026
423.3622252
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CIPLA
34.76
113978.9
EPS(TTM)
Face Value()
Div & Yield %
40.59
2
0.92
 

cipla ltd
USFDA inspects Cipla subsidiary's manufacturing unit in New York
Jul 18,2026

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).

The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.